Haemate P

Haemate P is a prescription injectable solution that contains human coagulation factor VIII and von Willebrand factor. It is used to replace deficient clotting proteins in patients with hemophilia A or von Willebrand disease, helping to restore normal hemostasis. The product is manufactured for the European market and administered intravenously under medical supervision.

Haemate P is indicated for the management of bleeding disorders related to factor VIII and von Willebrand factor deficiencies. It is used in both prophylactic and on‑demand treatment settings.

- Prevention of bleeding episodes in patients with severe hemophilia A. - Treatment of acute bleeding episodes in hemophilia A. - Management of von Willebrand disease, including surgery‑related bleeding. - Peri‑operative support for patients undergoing invasive procedures. - Long‑term prophylaxis to reduce the frequency of spontaneous bleeds.

Side effects of Haemate P may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common: - Headache - Fever or chills - Nausea or vomiting - Injection site reactions such as redness or swelling - Mild hypertension

Serious: - Development of inhibitors (antibodies) against factor VIII - Anaphylactic or severe allergic reactions - Thromboembolic events - Renal impairment in rare cases

When using Haemate P, certain precautions should be observed to ensure safety and efficacy.

- Assess for a history of inhibitors to factor VIII before initiating therapy. - Monitor for signs of allergic reactions during and after infusion. - Use caution in patients with cardiovascular disease or a history of thrombosis. - Adjust dosing in patients with renal or hepatic impairment as clinically indicated. - Ensure proper aseptic technique to prevent contamination of the injectable solution. - Educate patients on recognizing symptoms of inhibitor development.

Haemate P may interact with other medications or substances that affect coagulation or immune response.

Avoid: - Concurrent use of other clotting factor concentrates without medical guidance. - Administration of pro‑thrombotic agents in patients with a high risk of thrombosis.

Use with caution: - Immunosuppressive drugs that may alter inhibitor formation. - Antifibrinolytic agents (e.g., tranexamic acid) when combined with factor replacement. - Vaccines administered shortly before or after infusion, to monitor for immune reactions. - Medications that affect renal function, requiring dose adjustments.